For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post– ET-MF) Who Have Failed Ruxolitinib

Clinical Trial Details

You are being asked to consider participating in this study because you have been diagnosed with myelofibrosis (MF) and your prior treatment with a JAK Inhibitor is not effective enough or has become ineffective.

This is the first study of KRT-232 in MF and it will evaluate how well tolerated KRT-232 is when given to participants with MF, and whether KRT-232 can improve your MF. KRT-232 has been given to about 253 participants with different cancers and disorders (other than MF).
KRT-232 is a small molecule inhibitor and can reverse a mechanism through which unhealthy or tumor cells can survive and grow. This study will test if KRT-232 can restore the function of your healthy bone marrow cells and reduce the symptoms of your MF.

There are 2 parts planned for this study, Part A will test different doses and schedules of KRT-232 in 4 groups of participants to identify the recommended dose and schedule for Part B. Part B will continue to test if the recommended dose and schedule is a tolerable and effective treatment for MF.

If you consent to this research study, you will participate only in Part A. Currently Groups 1, 2, and 3 in Part A have completed enrollment. Therefore, if you have not already been assigned to a Group prior to signing this form, you will be assigned to Cohort 4b

Key Eligibility: 
  • 18 Years and older
  • Diagnosis of primary myelofibrosis or myelofibrosis that has occured after polycythemia vera or essential thrombocythemia
  • Failure of prior treatment with JAK inhibitor (Part A) or ruxolitinib (Part B)

Detailed eligibility will be reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan


Tania J. Curcio, NP, FNP-BC
(212) 746-2571

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group